Premium
Use of infliximab and other biologics in B ehçet disease
Author(s) -
Li J.,
Fernando S.,
Herkes G.
Publication year - 2014
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.12297
Subject(s) - medicine , infliximab , disease , vasculitis , dermatology , pediatrics
B ehçet disease is a multisystem vasculitis characterised by recurrent oral ulceration in conjunction with other manifestations. Neurological involvement or neuro‐ B ehçet disease is not common, but typically affects young men at its onset between the ages of 20 and 40 with significant long‐term morbidity and mortality. There is substantial case literature to support the use of tumour necrosis factor antagonists, notably infliximab, in the treatment of neuro‐ B ehçet disease.